Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
4 adjuvanted pandemic influenza candidate vaccines · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| 4 adjuvanted pandemic influenza candidate vaccines | BIOLOGICAL | - |
| 4 non-adjuvanted pandemic influenza candidate vaccines | BIOLOGICAL | - |
Inclusion criteria: * A male or female between, and including, 18 and 60 years of age at the time of the first vaccination. * Healthy subjects as established by medical history and clinical examination before entering into the study. * If the subject is female, she must be of non-childbearing poten...
4 adjuvanted pandemic influenza candidate vaccines are investigational vaccines being studied for use in influenza. They are designed to be given to adults aged between 18 and 60 years to evaluate their safety and immunogenicity as a pandemic influenza vaccine.
4 adjuvanted pandemic influenza candidate vaccines are being developed by GSK plc, a biopharma company listed on the stock exchange under the ticker GSK.
4 adjuvanted pandemic influenza candidate vaccines are in Phase 1 clinical development. They are investigational and have not been approved by regulatory authorities. One Phase 1 trial has been completed.
4 adjuvanted pandemic influenza candidate vaccines have one completed clinical trial, NCT00309634, titled 'Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years'. This Phase 1 study enrolled 400 participants in Belgium.
4 adjuvanted pandemic influenza candidate vaccines are pandemic influenza vaccine candidates. The clinical trial NCT00309634 evaluates the safety and immunogenicity of a pandemic influenza vaccine, which refers to these candidate vaccines.